JC06 Rec'd PCT/PTO 03 JUN 2005

170-1390 (Rev. 12-2004) Approved for use through 3/31/2007. OMB 0651-0021 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371

A power of attorney and/or change of address letter.

Other items or information:

20.

ATTTORNEY'S DOCKET NUMBER
3125 US0P
U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

INTERNATIONAL APPLICATION NO. PCT/JP2003/015535 INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED December 4, 2003 December 5, 2002 TITLE OF INVENTION 1.3-BENZOTHIAZINONE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME AND USE THEREOF APPLICANT(S) FOR DO/EO/US Masahiro KAJINO; Yutaka NAKAYAMA; Haruhide KIMURA Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. The US has been elected (Article 31). A copy of the International Application as filed (35 U.S.C. 371(c)(2)) is attached hereto (required only if not communicated by the International Bureau). has been communicated by the International Bureau. is not required, as the application was filed in the United States Receiving Office (RO/US). 6. 🗹 An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). is attached hereto. has been previously submitted under 35 U.S.C. 154(d)(4). 7 1 Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) are attached hereto (required only if not communicated by the International Bureau). have been communicated by the International Bureau. have not been made; however, the time limit for making such amendments has NOT expired. have not been made and will not be made. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 20 below concern document(s) or information included: An Information Disclosure Statement under 37 CFR 1.97 and 1.98. Cited References An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. A preliminary amendment. An Application Data Sheet under 37 CFR 1.76. A substitute specification.

This collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825.

A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).

A second copy of the published International Application under 35 U.S.C. 154(d)(4).

Page 1 of 2

Return Postcard; Certificate of Express Mailing; Cover Page International Application; Forms PCT/IB/304, 306; ISR

JC17 Rec'd PCT/PTO 03 JUN 2005

PTO-1390 (Rev. 12-2004)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICAT	ION NO. (if known, see	37 CFR 1.5) INTERNATIONAL AF	PLICATION NO.	ATTORNEY'S DOC	KET NUMBER
120	193154	<u> 20</u>	PCT/JP2003/01	5535	3125 US0P	
21. The following fees are submitted:						
a) Basic national fee\$300.00					\$	
b) Examination fee\$200.00					\$	
C) Search fee					\$·	
TOTAL OF ABOVE CALCULATIONS = \$1000.00 Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence					\$ 1,000.00	
listing or co	mputer program listing t					
additional s	0 sheets of paper or fra	╡				
Total Sheets Extra sheets		Number of each additional 50 or fraction thereof (round up to a whole number)				
83 - 100 =	0 /50 =	0		x \$250.00	\$ 0	
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e)).					\$	
CLAIMS NUMBER FII		ILED	LED NUMBER EXTRA RATE		\$	
Total claims	19	- 20 =	0	x \$50.00	\$	
Independent cla	ims 1	- 3 =	0	x \$200.00	\$	
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$360.00					\$	
TOTAL OF ABOVE CALCULATIONS =					\$ 1,000.00	•
Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by ½.					\$	
SUBTOTAL =					\$ 1,000.00	
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest					1	*
claimed priority date (37 CFR 1.492(f)). +					\$	
TOTAL NATIONAL FEE =					\$ 1,000.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +					\$	
TOTAL FEES ENCLOSED =					\$ 1,000.00	
					Amount to be refunded:	\$
					Amount to be charged:	\$ 1,000.00
a. A check in the amount of \$ to cover the above fees is enclosed.						
b. Please charge my Deposit Account No. 500799 in the amount of \$ 1,000.00 to cover the above fees. A duplicate copy of this sheet is enclosed.						
c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit t Account No. 500799. A duplicate copy of this sheet is enclosed.						
d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be Included on this form. Provide credit card information and authorization on PTO-2038.						
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revide (37 CFR 1.137(a) or (b)) must be filed and granted to restore the international Application to pending status.						
SEND ALL CORRESPONDENCE TO:						
Mark Chao, Ph.D., JD						
Takeda Pharmaceuticals North America, Inc						, <u>.</u>
475 Half Day Road Mark C					Chao, Ph.D., JD	
•	L 60069 USA					
(847)383-337	72 fax (847)383-3409	7,293				
		ION NUMBER ner No. 23,115				

10/537520 JC17 Rec'd PCT/PTO 03 JUN 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:

Based on PCT/JP2003/015535

Filed:

Intl. Filing 04 DECEMBER 2003

1st Inventor:

Masahiro KAJINO

For:

1,3-Benzothiazinone Derivatives and Process for

Producing the Same and Use Thereof

Atty. Dkt. No.

3125 US0P

Art Unit:

tba

Examiner

tba

Allowed:

Batch:

Dawn.

Paper No.

CERTIFICATE OF EXPRESS MAILING UNDER 37 CFR 1.10

USPS EXPRESS MAIL LABEL. No. EV 524904636 US

DATE IN:

June 3, 2005

Itemized Papers/Items:

- 1. This Certificate of Express Mailing and Return Postcard (2 pages)
- 2. Transmittal Letter for Filing under 35 USC 371 (2 pages X 2)
- 3. Specification total pages (83) including Claims 1-19 (pages 71-81, Abstract (1 page) and Sequence Listing (1 page)
- 4. Copies of Forms PCT/IB/ 304, 306 (2 pages)
- 5. Copy of Cover Page International Application (WO 2004/060881) (1 page)
- 6. Copy of International Search Report (3 pages)
- 7. Preliminary Amendment (3 pages)
- 8. Submission of Sequence Listing Requirements (1 page), CRF of Sequence Listing (2 pages), and IBM PC/AT format disk containing the CRF of the Sequence Listing.

The undersigned hereby certifies that the above itemized papers are together being deposited with the Express Mail Post Office to Addressee service of the United States Postal Service (USPS) in an envelope with sufficient postage, having the USPS Express Mail Label No. shown above, and addressed to:

MAIL STOP PCT P.O. BOX 1450

Commissioner for Patents Alexandria, VA 22313-1450

on this date, 6/3/05

Dated: 6/3/05

Gail I Winokur

Takeda Pharmaceuticals North America, Inc. Intellectual Property Department 475 Half Day Road Lincolnshire, IL 60069 USA